Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Prothya Biosolutions Acquisition

Accord Plasma B.V. Expands Its Global Reach in Plasma Therapy

Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has officially completed the acquisition of Prothya Biosolutions Belgium and its subsidiaries. This strategic move is aimed at enhancing Accord's efforts to improve global access to plasma-derived medicines, addressing the increasing demand for critical plasma therapies around the world.

Strategic Importance of the Acquisition

The acquisition of Prothya Biosolutions, one of Europe’s leading plasma fractionators, plays a crucial role in Accord's long-term strategy. Prothya operates large facilities in Amsterdam and Brussels, along with plasma collection centers throughout Hungary, employing approximately 1,200 skilled professionals. Integrating Prothya's extensive European expertise with Intas’s large-scale fractionation infrastructure in India will allow Accord to accelerate the development and availability of vital plasma-derived medicinal products (PDMPs) for patients across various regions.

Meeting Global Plasma Demand

Paul Tredwell, Global CEO of Accord Healthcare, highlighted the company’s commitment to ensuring that patients relying on plasma-based therapies have access to reliable and high-quality treatments. “Together with Prothya, we are better positioned to meet the rising global demand for plasma-derived medicines and provide patients worldwide with important, often under-prescribed therapies,” Tredwell stated.

About Accord Healthcare

Based in the United Kingdom, Accord Healthcare is among the fastest-growing pharmaceutical companies in Europe, boasting one of the largest market presences within the generics and biosimilars sector, distributing medicines in over 85 countries. This extensive global reach enables Accord to supply critical, affordable medications to national healthcare systems and support healthcare professionals in enhancing patient lives worldwide.

Accord is committed to remaining agile and innovative, consistently striving to improve products and enhance patient access. The company looks forward to paving new paths and achieving more for patients across the globe as it integrates Prothya’s operations into its framework.

This acquisition marks a significant milestone for Accord Plasma B.V., solidifying its potential to deliver life-saving treatments derived from plasma, thus expanding its foothold in the healthcare landscape. The collaboration aims not only at operational synergy but also at fulfilling a vital public health need amidst a growing global health crisis.

As the healthcare landscape continues to evolve, expertise and efficiency in plasma-derived therapies will be critical. The union of Accord and Prothya is poised to contribute positively to patient outcomes, making impactful strides towards better health services for those in need.

Conclusion

The completed acquisition of Prothya Biosolutions is a pivotal step for Accord Plasma B.V. in its mission to enhance patient care through innovative plasma therapies. This strategic initiative promises to strengthen their operational capabilities and customer reach, ultimately leading to a significant improvement in the availability of plasma-derived treatments worldwide. As they embark on this new journey, the expectant outcome will reshape the future of plasma therapies and elevate standards in patient care globally.